Selected research
Industry Research
Lipid-lowering Drugs Industry Research Report 2026
Market perspective
The global Lipid-lowering Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lipid-lowering Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lipid-lowering Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lipid-lowering Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lipid-lowering Drugs include Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Amgen Inc. and AbbVie, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lipid-lowering Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lipid-lowering Drugs Market by Company
Takeda Pharmaceutical Company Limited
Sun Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Merck & Co., Inc.
Pfizer, Inc.
GlaxoSmithKline plc
Amgen Inc.
AbbVie, Inc.
AstraZeneca PLC
Viatris (Mylan N.V.)
Dr. Reddy’s Laboratories Ltd.
Lipid-lowering Drugs Segment by Type
Statins & Combination
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibrates
PCSK9 Inhibitors
Others
Lipid-lowering Drugs Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Lipid-lowering Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lipid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lipid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lipid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lipid-lowering Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lipid-lowering Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lipid-lowering Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Statins & Combination
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibrates
- PCSK9 Inhibitors
- Others
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Sanofi
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- GlaxoSmithKline plc
- Amgen Inc.
- AbbVie, Inc.
- AstraZeneca PLC
- Viatris (Mylan N.V.)
- Dr. Reddy’s Laboratories Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lipid-lowering Drugs Market Size (2021-2032)
- 2.2.2 Global Lipid-lowering Drugs Sales (2021-2032)
- 2.2.3 Global Lipid-lowering Drugs Market Average Price (2021-2032)
- 2.3 Lipid-lowering Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Statins & Combination
- 2.3.3 Bile Acid Sequestrants
- 2.3.4 Cholesterol Absorption Inhibitors
- 2.3.5 Fibrates
- 2.3.6 PCSK9 Inhibitors
- 2.3.7 Others
- 2.4 Lipid-lowering Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lipid-lowering Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lipid-lowering Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Lipid-lowering Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Lipid-lowering Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Lipid-lowering Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lipid-lowering Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lipid-lowering Drugs, Product Type & Application
- 3.8 Global Manufacturers of Lipid-lowering Drugs, Established Date
- 3.9 Global Lipid-lowering Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical Company Limited
- 4.1.1 Takeda Pharmaceutical Company Limited Company Information
- 4.1.2 Takeda Pharmaceutical Company Limited Business Overview
- 4.1.3 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceutical Company Limited Recent Developments
- 4.2 Sun Pharmaceutical Industries Ltd.
- 4.2.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.2.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.2.3 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolio
- 4.2.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Lipid-lowering Drugs Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Novartis AG
- 4.4.1 Novartis AG Company Information
- 4.4.2 Novartis AG Business Overview
- 4.4.3 Novartis AG Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis AG Lipid-lowering Drugs Product Portfolio
- 4.4.5 Novartis AG Recent Developments
- 4.5 Merck & Co., Inc.
- 4.5.1 Merck & Co., Inc. Company Information
- 4.5.2 Merck & Co., Inc. Business Overview
- 4.5.3 Merck & Co., Inc. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck & Co., Inc. Lipid-lowering Drugs Product Portfolio
- 4.5.5 Merck & Co., Inc. Recent Developments
- 4.6 Pfizer, Inc.
- 4.6.1 Pfizer, Inc. Company Information
- 4.6.2 Pfizer, Inc. Business Overview
- 4.6.3 Pfizer, Inc. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer, Inc. Lipid-lowering Drugs Product Portfolio
- 4.6.5 Pfizer, Inc. Recent Developments
- 4.7 GlaxoSmithKline plc
- 4.7.1 GlaxoSmithKline plc Company Information
- 4.7.2 GlaxoSmithKline plc Business Overview
- 4.7.3 GlaxoSmithKline plc Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolio
- 4.7.5 GlaxoSmithKline plc Recent Developments
- 4.8 Amgen Inc.
- 4.8.1 Amgen Inc. Company Information
- 4.8.2 Amgen Inc. Business Overview
- 4.8.3 Amgen Inc. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Amgen Inc. Lipid-lowering Drugs Product Portfolio
- 4.8.5 Amgen Inc. Recent Developments
- 4.9 AbbVie, Inc.
- 4.9.1 AbbVie, Inc. Company Information
- 4.9.2 AbbVie, Inc. Business Overview
- 4.9.3 AbbVie, Inc. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AbbVie, Inc. Lipid-lowering Drugs Product Portfolio
- 4.9.5 AbbVie, Inc. Recent Developments
- 4.10 AstraZeneca PLC
- 4.10.1 AstraZeneca PLC Company Information
- 4.10.2 AstraZeneca PLC Business Overview
- 4.10.3 AstraZeneca PLC Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AstraZeneca PLC Lipid-lowering Drugs Product Portfolio
- 4.10.5 AstraZeneca PLC Recent Developments
- 4.11 Viatris (Mylan N.V.)
- 4.11.1 Viatris (Mylan N.V.) Company Information
- 4.11.2 Viatris (Mylan N.V.) Business Overview
- 4.11.3 Viatris (Mylan N.V.) Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolio
- 4.11.5 Viatris (Mylan N.V.) Recent Developments
- 4.12 Dr. Reddy’s Laboratories Ltd.
- 4.12.1 Dr. Reddy’s Laboratories Ltd. Company Information
- 4.12.2 Dr. Reddy’s Laboratories Ltd. Business Overview
- 4.12.3 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolio
- 4.12.5 Dr. Reddy’s Laboratories Ltd. Recent Developments
5 Global Lipid-lowering Drugs Market Scenario by Region
- 5.1 Global Lipid-lowering Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lipid-lowering Drugs Sales by Region: 2021-2032
- 5.2.1 Global Lipid-lowering Drugs Sales by Region: 2021-2026
- 5.2.2 Global Lipid-lowering Drugs Sales by Region: 2027-2032
- 5.3 Global Lipid-lowering Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Lipid-lowering Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Lipid-lowering Drugs Revenue by Region: 2027-2032
- 5.4 North America Lipid-lowering Drugs Market Facts & Figures by Country
- 5.4.1 North America Lipid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lipid-lowering Drugs Sales by Country (2021-2032)
- 5.4.3 North America Lipid-lowering Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Lipid-lowering Drugs Market Facts & Figures by Country
- 5.5.1 Europe Lipid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lipid-lowering Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Lipid-lowering Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Lipid-lowering Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lipid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lipid-lowering Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lipid-lowering Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lipid-lowering Drugs Market Facts & Figures by Country
- 5.7.1 South America Lipid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lipid-lowering Drugs Sales by Country (2021-2032)
- 5.7.3 South America Lipid-lowering Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Lipid-lowering Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lipid-lowering Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lipid-lowering Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lipid-lowering Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Lipid-lowering Drugs Sales by Type (2021-2032)
- 6.1.1 Global Lipid-lowering Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Lipid-lowering Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Lipid-lowering Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Lipid-lowering Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lipid-lowering Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Lipid-lowering Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lipid-lowering Drugs Sales by Application (2021-2032)
- 7.1.1 Global Lipid-lowering Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Lipid-lowering Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Lipid-lowering Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Lipid-lowering Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lipid-lowering Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Lipid-lowering Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lipid-lowering Drugs Value Chain Analysis
- 8.1.1 Lipid-lowering Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lipid-lowering Drugs Production Mode & Process
- 8.2 Lipid-lowering Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lipid-lowering Drugs Distributors
- 8.2.3 Lipid-lowering Drugs Customers
9 Global Lipid-lowering Drugs Analyzing Market Dynamics
- 9.1 Lipid-lowering Drugs Industry Trends
- 9.2 Lipid-lowering Drugs Industry Drivers
- 9.3 Lipid-lowering Drugs Industry Opportunities and Challenges
- 9.4 Lipid-lowering Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst